Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease

Recruiting now · Phase 2

Conditions studied: IgAN, C3G, Complement-mediated Kidney Disease, IgA Nephropathy (IgAN), IC-MPGN

In brief

This Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated kidney diseases.

Key facts

Study ID

NCT06989359

Run by

ADARx Pharmaceuticals, Inc.

People needed

45

Starts

2025-08-28

Expected to finish

2029-06-01

Last updated by the study team

2026-07-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Mean eGFR greater than or equal to 30 mL/min/1.73m2
• Clinical evidence of active kidney disease
• Treated with supportive care including an ACE inhibitor or ARB if applicable
• Willing to receive required vaccinations
• Primary diagnosis of IgAN, C3G or IC-MPGN confirmed by a kidney biopsy

You may not qualify if…

• Hereditary or acquired complement deficiency
• Kidney transplant or renal replacement therapy
• History of solid organ transplant
• Other kidney disease
• History of recurrent invasive infections
• Received complement inhibitor treatments
• Active systemic viral, bacterial, or fungal infection
• Abnormal liver function

Where it is running

• ADARx Clinical Site — Doral, Florida, United States (enrolling)
• ADARx Clinical Site — Miami, Florida, United States (enrolling)
• ADARx Clinical Site — Pembroke Pines, Florida, United States (enrolling)
• ADARx Clinical Site — Iowa City, Iowa, United States (enrolling)
• ADARx Clinical Site — Shreveport, Louisiana, United States (enrolling)
• ADARx Clinical Site — Shelby, Michigan, United States (enrolling)
• ADARx Clinical Site — Great Neck, New York, United States (enrolling)
• ADARx Clinical Site — Columbus, Ohio, United States (enrolling)
• ADARx Clinical Site — Dakota Dunes, South Dakota, United States (enrolling)
• ADARx Clinical Site — Dallas, Texas, United States (enrolling)
• ADARx Clinical Site — Houston, Texas, United States (enrolling)
• ADARx Clinical Site — Liverpool, New South Wales, Australia (enrolling)
• ADARx Clinical Site — Wollongong, New South Wales, Australia (enrolling)
• ADARx Clinical Site — Sydney, Australia (enrolling)
• ADARx Clinical Site — Woolloongabba, Australia (enrolling)
• ADARx Clinical Site — Hong Kong, Hong Kong (enrolling)
• ADARx Clinical Site — Shatin, Hong Kong (enrolling)
• ADARx Clinical Site — Bergamo, Italy (enrolling)
• ADARx Clinical Site — Pavia, Italy (enrolling)
• ADARx Clinical Site — Wŏnju, Gangwon-do, South Korea (enrolling)
• ADARx Clinical Site — Gyeonggi-do, Gurogu, South Korea (enrolling)
• ADARx Clinical Site — Seoul, Gurogu, South Korea (enrolling)
• ADARx Clinical Site — Cheonan, South Korea (enrolling)
• ADARx Clinical Site — Daegu, South Korea (enrolling)
• ADARx Clinical Site — Gyeonggi-do, South Korea (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.